129 related articles for article (PubMed ID: 19660105)
1. Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview.
Pozniak A; Müller L; Salgo M; Jones JK; Larson P; Tweats D
AIDS Res Ther; 2009 Aug; 6():18. PubMed ID: 19660105
[TBL] [Abstract][Full Text] [Related]
2. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
3. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
Lutz WK
Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
[TBL] [Abstract][Full Text] [Related]
4. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
Müller L; Singer T
Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
[TBL] [Abstract][Full Text] [Related]
5. Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.
Rebiere H; Maggio AF; Gimeno P; Levaillant D; Civade C; Bonnet PA; Tissier MH
Pharmeur Sci Notes; 2008 Feb; 2008(1):17-20. PubMed ID: 18430402
[TBL] [Abstract][Full Text] [Related]
6. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
Gocke E; Bürgin H; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
[TBL] [Abstract][Full Text] [Related]
7. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
[TBL] [Abstract][Full Text] [Related]
8. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
Gocke E; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
[TBL] [Abstract][Full Text] [Related]
9. General 4-week toxicity study with EMS in the rat.
Pfister T; Eichinger-Chapelon A
Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
[TBL] [Abstract][Full Text] [Related]
10. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
Gerber C; Toelle HG
Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
[TBL] [Abstract][Full Text] [Related]
11. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
Gocke E; Ballantyne M; Whitwell J; Müller L
Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
Lavé T; Birnböck H; Götschi A; Ramp T; Pähler A
Toxicol Lett; 2009 Nov; 190(3):303-9. PubMed ID: 19695315
[TBL] [Abstract][Full Text] [Related]
13. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU.
Gocke E; Müller L
Mutat Res; 2009 Aug; 678(2):101-7. PubMed ID: 19376265
[TBL] [Abstract][Full Text] [Related]
14. The Viracept-EMS case: impact and outlook.
Walker VE; Casciano DA; Tweats DJ
Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
[TBL] [Abstract][Full Text] [Related]
15. Absence of embryo-fetal toxicity in rats or rabbits following oral dosing with nelfinavir.
Burns-Naas LA; Webber S; Stump DG; Holson JF; Masarjian L; Zorbas M
Regul Toxicol Pharmacol; 2003 Dec; 38(3):291-303. PubMed ID: 14623480
[TBL] [Abstract][Full Text] [Related]
16. Quantitative dose-response analysis of ethyl methanesulfonate genotoxicity in adult gpt-delta transgenic mice.
Cao X; Mittelstaedt RA; Pearce MG; Allen BC; Soeteman-Hernández LG; Johnson GE; Bigger CA; Heflich RH
Environ Mol Mutagen; 2014 Jun; 55(5):385-99. PubMed ID: 24535894
[TBL] [Abstract][Full Text] [Related]
17. In vivo genotoxicity of EMS: statistical assessment of the dose response curves.
Gocke E; Wall M
Toxicol Lett; 2009 Nov; 190(3):298-302. PubMed ID: 19857797
[TBL] [Abstract][Full Text] [Related]
18. Synergism of mutant frequencies in the mouse lymphoma cell mutagenicity assay by binary mixtures of methyl methanesulfonate and ethyl methanesulfonate.
Tarlo KS; Boehnke M; Chin B
Mutat Res; 1988 Oct; 206(2):239-46. PubMed ID: 3173391
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the genotoxicity of ethylnitrosourea and ethyl methanesulfonate in lacZ transgenic mice (Muta Mouse).
Suzuki T; Hayashi M; Wang X; Yamamoto K; Ono T; Myhr BC; Sofuni T
Mutat Res; 1997 Dec; 395(1):75-82. PubMed ID: 9465915
[TBL] [Abstract][Full Text] [Related]
20. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]